Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A patient-reported outcome measure for effect of glucocorticoid therapy in adults with inflammatory diseases is needed: report from the OMERACT 2016 special interest group|
|Citation:||Journal of Rheumatology, 2017; 44(11):1754-1758|
|Publisher:||Canadian Rheumatology Association|
|Rachel J. Black, Joanna C. Robson, Susan M. Goodman, Elizabeth Hoon, Lana Y.H. Lai, Lee S. Simon|
|Abstract:||Objective. The need for a standardized instrument to measure the effect of glucocorticoid (GC) therapy has been well documented in the literature. The aim of the first GC Special Interest Group was to define a research agenda around the development of a patient-reported outcome measure (PROM) in this area. Methods. The results of a background literature search and the preliminary results of a pilot survey and 2 qualitative studies were presented to facilitate the development of a research agenda. Results. It was agreed that there was a need for a data-driven PROM that identified both positive and negative effects of GC therapy to be used across all inflammatory indications for systemic GC use in adults. A research agenda was developed, consisting of further qualitative work to assess the effect of GC across different groups including various indications for GC use, different age groups, different dosages, and duration of treatment.|
Patient Reported Outcome Measures
|Rights:||The Journal of Rheumatology Copyright © 2017. All rights reserved.|
|Appears in Collections:||Aurora harvest 4|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.